Literature DB >> 1782979

Elimination of flecainide as a function of urinary flow rate and pH.

R Hertrampf1, U Gundert-Remy, J Beckmann, U Hoppe, W Elsässer, H Stein.   

Abstract

In order to evaluate the influence of urinary flow rate at different pH values on the pharmacokinetics of the basic antiarrhythmic drug flecainide 7 healthy men received 50 mg flecainide under 4 different conditions: 1. acidic urine (pH 5) and a high fluid load (125 ml.h-1) 2. acidic urine (pH 5) and a low fluid load (25 ml.h-1) 3. alkaline urine (pH 8) and a high fluid load (125 ml.h-1) 4. alkaline urine (pH 8) and a low fluid load (25 ml.h-1) At acidic pH the half-life, the amount of unchanged drug in the urine (Ae), renal clearance (CLR) and area under the curve (AUC) were independent of the fluid load. At alkaline pH Ae (5.8 vs 2.6 mg) and CLR (73 vs 33 ml.min-1) were significantly affected by fluid load (high vs low), whereas half-life and AUC were not different (15.7 vs 16.0 h, 1480 vs 1540 ng.ml-1.h). When comparing acidic and alkaline urinary pH conditions, half-life, Ae, CLR, and AUC were different. For a high fluid load the values at acidic vs alkaline pH were half-life 10.0 vs 15.7 h; Ae 15.9 vs 5.8 mg; CLR 288 vs 73 ml.min-1; AUC 976 vs 1480 ng.ml-1.h. For a low fluid load the corresponding values at acidic vs alkaline pH were half-life 10.1 vs 16.0 h; Ae 15.9 vs 2.6 mg; CLR 267 vs 33 ml.min-1; AUC 1045 vs 1540 ng.ml-1.h. It is concluded that urinary pH affects flecainide pharmacokinetics independently of urinary flow rate, and that a high flow enhances the elimination of flecainide only with an alkaline urine. This effect of flow rate does not appear to be of clinical relevance.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1782979     DOI: 10.1007/BF00280108

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  5 in total

1.  The influence of urinary pH on flecainide excretion and its serum pharmacokinetics.

Authors:  K A Muhiddin; A Johnston; P Turner
Journal:  Br J Clin Pharmacol       Date:  1984-04       Impact factor: 4.335

2.  Application of a bonded-phase extraction column for rapid sample preparation of flecainide from human plasma for high-performance liquid chromatographic analysis--fluorescence or ultraviolet detection.

Authors:  S F Chang; A M Miller; J M Fox; T M Welscher
Journal:  Ther Drug Monit       Date:  1984       Impact factor: 3.681

Review 3.  Flecainide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy.

Authors:  B Holmes; R C Heel
Journal:  Drugs       Date:  1985-01       Impact factor: 9.546

4.  Pharmacodynamics and side effects of flecainide acetate.

Authors:  D M Salerno; G Granrud; P Sharkey; J Krejci; T Larson; D Erlien; D Berry; M Hodges
Journal:  Clin Pharmacol Ther       Date:  1986-07       Impact factor: 6.875

5.  Flecainide pharmacokinetics in healthy volunteers: the influence of urinary pH.

Authors:  A Johnston; S Warrington; P Turner
Journal:  Br J Clin Pharmacol       Date:  1985-10       Impact factor: 4.335

  5 in total
  3 in total

1.  Effect of CYP2D6 genotype on flecainide pharmacokinetics in Japanese patients with supraventricular tachyarrhythmia.

Authors:  Kosuke Doki; Masato Homma; Keisuke Kuga; Kazutomi Kusano; Shigeyuki Watanabe; Iwao Yamaguchi; Yukinao Kohda
Journal:  Eur J Clin Pharmacol       Date:  2006-08-30       Impact factor: 2.953

2.  Influence of urine pH and urinary flow on the renal excretion of memantine.

Authors:  S Freudenthaler; I Meineke; K H Schreeb; E Boakye; U Gundert-Remy; C H Gleiter
Journal:  Br J Clin Pharmacol       Date:  1998-12       Impact factor: 4.335

3.  Presence of an H+/Quinidine Antiport System in Madin-Darby Canine Kidney Cells.

Authors:  Miki Fukao; Eri Kondo; Hiroki Nishino; Ryutaro Hattori; Asuka Horie; Yukiya Hashimoto
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-12       Impact factor: 2.441

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.